Wolverine Recovery Research Stack

£78.99

Purity: ≥ 99%

£78.99

Wolverine Recovery Research Stack

Name: Wolverine Recovery Research Stack
Brand: Pure Grade Labs
Price: 78.99 GBP
Availability: OutOfStock

£78.99

Purity: ≥ 99%

£78.99

TENDON & LIGAMENT - Fibroblast migration, and cell repair research

VASCULAR REPAIR - Angiogenesis and blood vessel ingrowth research

METABOLIC SAFETY - IGF-1 feedback preservation and glycaemic safety research

MATRIX REMODELLING - Collagen, elastin, GAG synthesis and ECM architecture research

The Most Referenced Recovery Stack in the Research Literature.

The Most Referenced Recovery Stack in the Research Literature. BPC-157 and TB-500 are the two most studied peptides in structural tissue repair research - they appear together in forum discussions, research protocols, and the wider literature more consistently than any other peptide pair. GHK-Cu is the third compound in this stack, operating through a different mechanism that none of the other two addresses: extracellular matrix remodelling, collagen synthesis, and angiogenesis-mediated tissue reconstruction.

BPC-157 works at the cellular signalling level - VEGFR2-PI3K-Akt-eNOS and Src-caveolin-1 pathways that drive angiogenesis, fibroblast migration, and cell protection. TB-500 works through thymosin beta-4, regulating actin dynamics and systemic immune-modulated healing. GHK-Cu works at the extracellular matrix level, directly stimulating the fibroblast production of structural proteins and the vascular ingrowth required to sustain them. Three layers. Three mechanisms. One protocol.

BPC-157

Synthetic pentadecapeptide (15 amino acids) isolated from human gastric juice by Sikiric et al., 1993. Designated "stable" for its resistance to enzymatic degradation. Studied across tendon, ligament, bone, muscle, vascular, and gastrointestinal tissue models for over 30 years. Evidence spans VEGFR2 pathway activation, angiogenesis induction, fibroblast migration, collagen organisation, and cytoprotection. As of 2025, a systematic review in HSS Journal characterised it as having extensive preclinical evidence across orthopaedic and sports medicine applications, with early-phase human data in knee, bladder, and IV safety studies.

TB-500

Synthetic form of Thymosin Beta-4 (TB4), a naturally occurring 43-amino-acid peptide found in virtually all mammalian cells and particularly concentrated in platelets and wound fluid. Acts as the primary regulator of G-actin sequestration - controlling the pool of actin available for cytoskeletal dynamics and cell migration. Studied for systemic, blood-borne distribution (unlike BPC-157's more localised action), immune modulation, anti-inflammatory effects, and promotion of cardiac and muscle regeneration. Research shows TB4 is released naturally at sites of injury, making TB-500 a synthetic amplification of an endogenous repair signal.

GHK-Cu

Naturally occurring human tripeptide (Glycyl-L-Histidyl-L-Lysine) copper chelate, first isolated from human plasma in 1973. Serum levels decline from approximately 200 ng/ml at age 20 to 80 ng/ml by age 60. Studied for stimulation of collagen and elastin synthesis, angiogenesis via VEGF and bFGF upregulation, glycosaminoglycan production, anti-inflammatory activity, and regulation of over 4,000 human genes involved in tissue repair. Unlike BPC-157 and TB-500, GHK-Cu specifically targets the extracellular matrix architecture - the structural scaffold that healed tissue must be built on.

BPC-157 Sequence (15 AA / Pentadecapeptide): H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH - MW: 1,419.6 g/mol - CAS: 137525-51-0

TB-500 (Thymosin Beta-4) Sequence (43 AA): Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-NH2 - CAS: 77591-33-4

GHK-Cu (Tripeptide Copper Chelate): Gly-His-Lys · Cu(II) - MW: 340.38 g/mol - CAS: 49557-75-7

2025 | HSS Journal | Systematic Review

BPC-157 in orthopaedic sports medicine: systematic review characterises mechanism and preclinical evidence across fractures, tendons, ligaments, and muscle

Vasireddi et al. conducted a systematic review of BPC-157 literature from database inception to June 2024 across PubMed, Cochrane, and Embase, specifically from an orthopaedic and sports medicine perspective. The review characterised BPC-157's mechanism of action via VEGFR2-PI3K-Akt-eNOS and Src-caveolin-1 signalling pathways, noting preclinical evidence for application in fractures, tendon ruptures, ligament tears, and muscle injuries across multiple animal models. The review identified the breadth and consistency of BPC-157's preclinical tissue repair data as compelling, while concluding that human clinical trials remain a significant gap. As of the review date, human data was limited to small pilot studies in knee pain (intra-articular), interstitial cystitis, and IV pharmacokinetics.

Vasireddi N, et al. HSS J. 2025:15563316251355551. PubMed →

2011 | Journal of Applied Physiology | In Vitro

BPC-157 accelerates tendon fibroblast migration and confers cytoprotection against oxidative stress

Chang et al. examined BPC-157's cellular mechanisms using tendon explant cultures and isolated tendon fibroblasts. BPC-157 significantly accelerated outgrowth from tendon explants and markedly increased fibroblast migration in a dose-dependent manner in vitro. Critically, treated fibroblasts demonstrated significantly improved survival under hydrogen peroxide-induced oxidative stress - a finding that goes beyond simple proliferation stimulation and suggests BPC-157 protects the cellular machinery of repair from the oxidative environment that is a normal feature of injured tissue. This cytoprotective effect is mechanistically distinct from the angiogenic effects characterised elsewhere and supports the compound's role in maintaining the cellular capacity for repair throughout the healing process.

Chang CH, et al. J Appl Physiol. 2011;110(3):774-780. PubMed →

2010 | Journal of Cell Science | In Vitro / Animal

Thymosin Beta-4 promotes cardiac progenitor cell migration and differentiation via actin dynamics and systemic signalling

Smart et al. investigated TB4's role in cardiac repair, demonstrating that TB4 activates epicardial progenitor cells and promotes their migration into damaged cardiac tissue. TB4-treated mice showed improved cardiac function and enhanced myocardial regeneration post-injury. The study characterised the actin sequestration mechanism (G-actin regulation via Wnt and PINCH signalling) as the basis for TB4's ability to mobilise progenitor cells, and confirmed TB4's systemic distribution as a blood-borne signal enabling distal progenitor recruitment. This systemic reach - absent from BPC-157's localised mechanism - is what makes TB-500 the long-range component of this recovery stack: it recruits repair-competent cells from throughout the system, not just from the immediate injury site.

Smart N, et al. J Cell Sci. 2010;123(Pt 8):1229-1237. PubMed →

2000 | Journal of Investigative Dermatology | Animal Study

GHK-Cu injections produce 396-538% increases in wound collagen content - with simultaneous GAG modulation

Maquart et al. studied GHK-Cu in implanted wound chamber models in rats, measuring collagen and glycosaminoglycan (GAG) content at days 7, 12, 18, and 22. GHK-Cu injections significantly increased collagen content in wound chambers at days 18 and 22 to 396% and 538% of controls respectively (p<0.05). Parallel increases in GAG content were also documented (179-191% of controls at days 12-22, p<0.05). GAG electrophoresis revealed that GHK-Cu specifically modulated the relative proportions of hyaluronic acid, dermatan sulfate, and chondroitin sulfate - the GAGs that regulate collagen fibrillogenesis and determine the architectural quality of the reconstructed matrix. This paper remains the most quantitatively specific demonstration of GHK-Cu's extracellular matrix-building effects in wound models.

Maquart FX, et al. J Invest Dermatol. 2000;115(6):962-968. PubMed →

Every Wolverine Recovery Research Stack ships with a batch-specific Certificate of Analysis from an independent third-party analytical laboratory, covering all three compounds. The COA confirms identity, purity by HPLC, and absence of contaminants.

All three compounds are supplied as lyophilised (freeze-dried) solids. Bacteriostatic water is required for reconstitution and is available separately. Storage specifications below apply to both vials.

Temperature: -20°C Long-term storage. For short-term use (up to 4 weeks), 2-8°C is acceptable.

Light Sensitivity: Light-Sensitive. Store in original opaque vial. Avoid direct UV or prolonged exposure to light.

Shelf Life: 24 Months. Lyophilized, sealed, stored at -20°C. Batch expiry printed on vial label.

Allow sealed vials to reach room temperature before opening to minimise moisture introduction. Bacteriostatic water is supplied ready to use - no preparation required.
Use the included bacteriostatic water as reconstitution solvent. Add solvent slowly down the inside wall of the vial - do not inject directly onto the lyophilised cake.
Gently swirl each vial until fully dissolved. Do not vortex or shake vigorously. Both compounds dissolve readily in BAC water.
Once reconstituted, store at 2-8°C. Use within 28 days. Do not freeze reconstituted solution.
Discard if solution appears cloudy, discoloured, or contains particulate matter.

BPC-157, TB-500, and GHK-Cu supplied by Pure Grade Labs are intended exclusively for in vitro research and laboratory use. These products are not approved for human or veterinary use by any regulatory authority.

BPC-157 is classified as a Category 2 bulk drug substance by the FDA (as of September 2023), restricting its inclusion in compounded medications in the United States.
All three compounds are prohibited in sport by WADA under the S0 Unapproved Substances or S2 Peptide Hormones categories. Athletes subject to drug testing should verify current classifications.
Pure Grade Labs makes no claims regarding therapeutic or clinical efficacy in humans.
Purchasers are solely responsible for compliance with all applicable laws and regulations in their jurisdiction.

All research summaries and study citations are provided for informational context only and do not constitute medical advice or recommendation for human use.